(firstQuint)Study of Pazopanib and Ixabepilone in Patients With Solid Tumors.

 Treatment with ixabepilone will be given at an assigned dose as a 3 hour intravenous infusion on day 1 of a 21 day cycle.

 Treatment with pazopanib will be given at an assigned dose by mouth once a day, beginning on day 1 and continuing daily.

 Disease assessment will be done every 2 cycles (6 weeks) with treatment continuing until disease progression, unacceptable toxicity or patient refusal.

.

 Study of Pazopanib and Ixabepilone in Patients With Solid Tumors@highlight

This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.

